Skip to main content
SpringerLink
Log in

Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz

Drug treatment of chronic heart failure

  • WEITERBILDUNG · ZERTIFIZIERTE FORTBILDUNG
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Zusammenfassung

Die medikamentöse Therapie von Patienten mit chronischer Herzinsuffizienz wird aufgrund neuer Studien ständig verändert. Sie hat leitliniengetreu zu erfolgen. Neuerungen und der aktuelle Stand der Forschung sind in diesem Artikel wiedergegeben.

Summary

Drug treatment of chronic heart failure is undergoing continuous modifications according to the data of new trials. Treatment has to be adjusted to current guidelines. The state of the art of medical treatment of chronic heart failure is addressed in this report.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Böhm M (2000) Definition der Herzinsuffizienz. In: Böhm M (Ed) Georg Thieme Verlag, Stuttgart-New York 1–4

  2. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435

    Google Scholar 

  3. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302

    Google Scholar 

  4. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691

    Google Scholar 

  5. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN (1999) Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 99:2658–2664

    CAS  PubMed  Google Scholar 

  6. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675

    Article  CAS  PubMed  Google Scholar 

  7. Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, Dahlof B, Devereux RB (2002) Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 39:739–743

    Article  CAS  PubMed  Google Scholar 

  8. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. Lancet 362:772–776

    Article  CAS  PubMed  Google Scholar 

  9. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100:1056–1064

    CAS  PubMed  Google Scholar 

  10. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771

    CAS  PubMed  Google Scholar 

  11. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677

    CAS  PubMed  Google Scholar 

  12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMOverall programme. Lancet 362:759–766

    CAS  PubMed  Google Scholar 

  13. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van De WF, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906

    Article  CAS  PubMed  Google Scholar 

  14. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752

    CAS  PubMed  Google Scholar 

  15. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587

    Article  CAS  PubMed  Google Scholar 

  16. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlof B, Aalto T, Gerdts E, Devereux RB (2002) Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105:1071–1076

    Article  PubMed  Google Scholar 

  17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153

    CAS  PubMed  Google Scholar 

  18. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781

    Article  CAS  PubMed  Google Scholar 

  19. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat Ph, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker StD, Thompson SG, Poole-Wilson PhA on behalf of the SENIORS Investigators (2005) Fast-track randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. European Heart Journal 26:215–225

    CAS  PubMed  Google Scholar 

  20. Lin M, Sumimoto T, Hiwada K (1995) Left ventricular geometry and cardiac function in mild to moderate essential hypertension. Hypertens Res 18:151–157

    CAS  PubMed  Google Scholar 

  21. Böhm M (2002) Pathophysiology of heart failure today. Herz 27:75–91

    PubMed  Google Scholar 

  22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DA, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult—summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 112:1825–1852

    Article  Google Scholar 

  23. Hoppe UC, Böhm M, Dietz R, Hanrath P, Kroemer HK, Osterspey A, Schmaltz AA, Erdmann E (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 94:488–509

    Article  CAS  PubMed  Google Scholar 

  24. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen M, Piérard L, Remme WJ (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26:1115–1140

    Article  PubMed  Google Scholar 

  25. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670–1676

    Article  CAS  PubMed  Google Scholar 

  26. The Captopril-Digoxin Multicenter Research Group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259:539–544

    Google Scholar 

  27. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310

    CAS  PubMed  Google Scholar 

  28. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675

    Article  CAS  PubMed  Google Scholar 

  29. Teerlink JR, Massie BM (1999) Betaadrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 84:94R–102R

    Article  CAS  PubMed  Google Scholar 

  30. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (1999) Lancet 353:9–13

    Google Scholar 

  31. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF) (1999) Lancet353:2001–2007

  32. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807–2816

    CAS  PubMed  Google Scholar 

  33. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94:2800–2806

    CAS  PubMed  Google Scholar 

  34. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349–1355

    Article  CAS  PubMed  Google Scholar 

  35. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13

    CAS  PubMed  Google Scholar 

  36. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P (1987) Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57:17–22

    CAS  PubMed  Google Scholar 

  37. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717

    CAS  PubMed  Google Scholar 

  38. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321

    Article  CAS  PubMed  Google Scholar 

  39. Böhm M (2002) Are cardiac glycosides still needed in the treatment of cardiac insufficiency? Dtsch Med Wochenschr 127:2133–2138

    PubMed  Google Scholar 

  40. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533

    Google Scholar 

  41. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403–1411

    Article  CAS  PubMed  Google Scholar 

  42. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289:871–878

    CAS  PubMed  Google Scholar 

  43. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547–1552

    CAS  PubMed  Google Scholar 

  44. Cohn J, Johnson G, Ziesche S, Cobb FR, Francis GS, Tristani FE, Smith R, Dunkman WB, Loeb HS, Wong M, Bhat G, Glogman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in treatment of chronic congestive heart failure. N Engl J Med 325:303–310

    CAS  PubMed  Google Scholar 

  45. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049–2057

    CAS  PubMed  Google Scholar 

  46. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981–2997

    Google Scholar 

  47. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L (1997) The effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure. Circulation 96:856–863

    CAS  PubMed  Google Scholar 

  48. Packer M, O’Conner Ch M, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the prospective randomized amlopidine survival evaluation study group (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107–1114

    Article  CAS  PubMed  Google Scholar 

  49. The Danish Verapamil Infarction Trial II-(DAVIT II) (1990) Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 66:779–785

    Google Scholar 

  50. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E (1993) Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 153:345–353

    Article  CAS  PubMed  Google Scholar 

  51. The Israeli Sprint Study Group (1988) Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 9:354–364

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar

    M. Böhm,  N. Werner &  M. Kindermann

  2. Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, 66421, Homburg/Saar

    M. Böhm &  M. Kindermann

  3. Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Sigmund-Freud-Str. 25, 53105, Bonn

    N. Werner

Authors
  1. M. Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Kindermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to M. Böhm or N. Werner.

Additional information

Zertifizierte Fortbildung für Kliniker und Niedergelassene Die Teilnahme an der CME-Fortbildung der Zeitschrift Clinical Research in Cardiology in Zusammenarbeit mit der Deutschen Gesellschaft für Kardiologie erfolgt ausschließlich online auf www.dgk.org/cme und steht allen interessierten Ärztinnen und Ärzten unabhängig vom Abonnement der Zeitschrift offen.

Registrierung/Anmeldung Nehmen Sie erstmals teil, werden Sie nach Eingabe der Antworten nach einigen persönlichen Angaben gefragt und erhalten dann individuelle Zugangsdaten zur weiteren Nutzung; DGK- und Akademiemitglieder halten bitte ihre Mitgliedsnummer und Passwort parat.

Zertifizierte Qualität Die Fortbildungseinheiten sind bei der Nordrheinischen Akademie für ärztliche Fort- und Weiterbildung der Ärztekammer Nordrhein zertifiziert und sind damit auch für andere Ärztekammern anerkennungsfähig. Nutzen Sie also Ihre Chance, sich weiterzubilden und CME-Punkte zu erwerben.

Online teilnehmen und CME-Punkte sammeln Die Teilnahme ist nur online unter www.dgk.org/cme möglich. Nach erfolgreicher Beantwortung von mindestens 7 der 10 Fragen können Sie sich Ihre Urkunde direkt ausdrucken. Zusätzlich erhalten Sie per E-Mail eine Bestätigung der Teilnahme und der CME-Punkte, damit Sie sich das Zertifikat gegebenenfalls später ausdrucken können.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Böhm, M., Werner, N. & Kindermann, M. Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clin Res Cardiol 95 (Suppl 4), 36–56 (2006). https://doi.org/10.1007/s00392-006-2008-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-006-2008-9

Schlüsselwörter

Key words

Search

Navigation